thesilkroadtoday
Seoul, South Korea — Biostar Group has announced the launch of the official YouTube channel of its Chairman, Dr. Jeong Chan Ra, under the title “Angel Stem Cells!”, marking a new step in the company’s efforts to strengthen communication with supporters, patients, researchers, and the wider public.
The new channel has been established to provide a more transparent and direct platform through which audiences can access the latest developments within Biostar Group and gain a deeper understanding of its pioneering work in regenerative medicine and stem cell research.
According to the announcement, the “Angel Stem Cells!” channel will serve as a comprehensive source of information about the company’s major projects, technological achievements, and long-term vision. Subscribers will be able to follow updates on Biostar’s current activities, future plans, and strategic initiatives aimed at advancing stem cell therapies and innovative biomedical solutions.
The channel will also offer insights into Biostar’s core businesses, presenting information about the company’s existing technologies as well as its future development goals. Through educational and informative video content, viewers will gain a clearer understanding of the scientific and clinical work being carried out by the organization.
A distinctive feature of the channel is its role as a direct communication platform between Dr. Jeong Chan Ra and the public. Through regular video messages, the Biostar chairman will share reliable information, personal perspectives, and updates on the company’s progress, fostering greater trust and engagement with audiences around the world.
Biostar Group has invited supporters and members of the public to subscribe to the channel in order to receive timely access to new video content and stay informed about the latest developments in stem cell science and regenerative medicine.
The launch of “Angel Stem Cells!” reflects Biostar Group’s commitment to openness, innovation, and global outreach as it continues its mission of advancing healthcare through cutting-edge stem cell technologies.
In a recent video entitled “Discussion on the JointStem FDA Meeting Minutes and Approval Application Schedule” — and recent public information about JointStem and Dr. Jeong Chan Ra’s FDA strategy, the discussion appears to focus on the following key topics:
1. Review of FDA Meeting Minutes
Dr. Jeong Chan Ra and participants discuss the outcomes of recent FDA meetings concerning JointStem, the stem cell therapy for severe knee osteoarthritis.
Particular attention is given to FDA feedback on clinical efficacy endpoints, manufacturing controls (CMC), and the regulatory pathway toward approval.
2. Accelerated Approval Strategy
The discussion examines the possibility of pursuing FDA Accelerated Approval based on improvements in pain (VAS) and joint function (WOMAC) as surrogate or intermediate clinical endpoints.
Participants explain why these measures may support earlier market authorization while confirmatory studies continue afterward.
3. Breakthrough Therapy and FDA Interactions
JointStem’s Breakthrough Therapy designation is highlighted as a significant advantage because it allows more frequent communication with the FDA and may shorten development timelines.
The panel discusses how FDA consultations are helping refine the development and approval strategy.
4. Clinical Trial and Approval Timeline
The speakers review the expected schedule for:
Finalizing the FDA consultation process.
Determining whether Accelerated Approval is feasible.
Submitting the Biologics License Application (or equivalent approval package).
Launching Phase III studies if required.
Publicly announced plans have suggested FDA meetings in 2026, potential application submission after regulatory alignment, and a goal of U.S. commercialization as early as 2027 if the accelerated pathway is accepted.
5. Long-Term Vision
Dr. Ra likely emphasizes that JointStem is intended not merely to reduce symptoms but to offer regenerative treatment that may delay or avoid knee replacement surgery.
The discussion frames FDA approval as a major milestone for global expansion and wider patient access.
The roundtable discussion reviews the outcomes of recent FDA consultations regarding JointStem, focusing on regulatory feedback, the feasibility of an accelerated approval pathway, and the timetable for future submissions. Dr. Jeong Chan Ra explains how the FDA meeting minutes help clarify requirements for approval, discusses the use of pain and functional improvement data as key efficacy measures, and outlines the company’s strategy for advancing JointStem toward U.S. market authorization. The conversation also addresses upcoming regulatory milestones, potential Phase III requirements, and the broader vision of establishing JointStem as a regenerative treatment for severe knee osteoarthritis.
To watch press here
